Skip to content
Coming Soon·Opens soon·Synced from source July 6, 2026

Rigor and Reproducibility for Biomarkers in Type 1 Diabetes Clinical Research

National Institutes of Health

Posted
Feb 4, 2026
Closes
No deadline published by the funder
Last verified
Jul 6, 2026

Classification and identifiers

Solicitation number
RFA-DK-27-140
Assistance listing (CFDA)
93.847

Amount

Amount not published by the funder

Who can apply

Special districtsNonprofits (non-501c3)School districtsNonprofitsCounty governmentsPublic universities

Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).

About this opportunity

The main goal of this initiative is to establish a consortium with the overarching goal to advance the systematic identification, rigorous evaluation, validation, and assays harmonization of biomarkers that are critical to the prevention, diagnosis, and clinical management of Type 1 Diabetes (T1D). Despite significant advances in T1D research, there remains an urgent need for reliable and reproducible biomarkers that can capture the complexity of autoimmune processes, metabolic dysregulation, and individual patient variability. This initiative will leverage state-of-the-art methodologies in clinical chemistry, genomics, proteomics, metabolomics, immunophenotyping, and imaging, coupled with longitudinal patient cohorts and mining of Electronic Health Records (EHR). Within this consortium ma...

Finding similar opportunities...